When domestic companies will win patent suits over ‘Revlimid’?

Domestic pharmaceutical companies have filed patent suits to preoccupy the market of the multiple myeloma therapy whose substance patent will be expired next year, ‘Revlimid,’ but they continued failure.  

Celgene’s Revlimid(generic name: lenalidomide) is a leading company in the multiple myeloma treatment market, which recorded USD 5.8 billion(KRW 6.9 trillion) globally last year. Even throug...